Trial NCT05135650

View at ClinicalTrials.gov 
Org. Study IDs: RG1121602
Secondary IDs: 10691 NCI-2021-05949

Last trial update was posted on 2023-06-09

MeSH Interventions

Antibodies Antibodies, Monoclonal Antineoplastic Agents, Immunological Immunoglobulins Sotrovimab

MeSH Conditions

COVID-19 Neoplasms

Other Conditions

COVID-19 Infection Hematopoietic and Lymphoid Cell Neoplasm Malignant Solid Neoplasm

Stopping Reasons

Terminated due to FDA withdrawal of the emergency use authorization (EUA) for sotrovimab

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID